Faeth Therapeutics, Inc. - 10-Q Filing
Faeth Therapeutics reports Q3 financial position characterized by ongoing R&D and G&A expenses with significant equity-based compensation activity.
Tickers: $SNSE
Faeth Therapeutics reports Q3 financial position characterized by ongoing R&D and G&A expenses with significant equity-based compensation activity.
Tickers: $SNSE